Drugs / EMUGROBART
EMUGROBART
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07137585 | Sep 2025 → Sep 2026 overdue | obesity disorder, type 2 diabetes mellitus | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04708847 | Feb 2021 → Jun 2022 | — | Chugai Pharmaceutical | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06965413 | May 2025 → Sep 2026 overdue | obesity disorder | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05548556 | Feb 2023 → May 2025 overdue | facioscapulohumeral muscular dystrophy | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT05115110 | Jun 2022 → Oct 2026 expected | spinal muscular atrophy | Hoffmann-La Roche | Active not recruiting | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-09-28 | Chugai Pharmaceutical | Results Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA chugai-pharm.co.jp ↗
It was concluded that achieving the pre-specified efficacy objectives of clinically meaningful weight loss is unlikely. |
| 2026-03-23 | Chugai Pharmaceutical | Results Notice Regarding Discontinuation of Development of GYM329 (Emugrobart) in Spinal Muscular Atrophy (SMA) and Facioscapulohumeral Muscular Dystrophy (FSHD) chugai-pharm.co.jp ↗
While emugrobart showed a favorable safety profile and target engagement by reducing mature myostatin, it did not translate into the intended functional outcomes. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-28 | Chugai Pharmaceutical | Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA chugai-pharm.co.jp ↗ |
| 2026-03-23 | Chugai Pharmaceutical | Notice Regarding Discontinuation of Development of GYM329 (Emugrobart) in Spinal Muscular Atrophy (SMA) and Facioscapulohumeral Muscular Dystrophy (FSHD) chugai-pharm.co.jp ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMUGROBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068245 ↗ |
| Known as | GYM329 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04708847 ↗ |
| Known as | RG-6237 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068245 ↗ |
| Known as | RG-70240 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068245 ↗ |
| Known as | RO7204239 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06965413 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody that binds to human latent myostatin” NCT05548556 ↗ |
| Route | Subcutaneous | “GYM329 subcutaneous injection” NCT04708847 ↗ |